Used in targeted cancer immunotherapy, this antibody modulates the MER tyrosine kinase (MERTK) receptor, which plays a key role in suppressing immune responses within the tumor microenvironment. By inhibiting MERTK activity, it helps restore the ability of immune cells like macrophages and dendritic cells to recognize and eliminate cancer cells. It is being explored in preclinical and clinical settings to enhance the efficacy of other immunotherapies, particularly in solid tumors and hematologic malignancies. Its application supports the development of treatments aimed at overcoming immune evasion by cancer cells.